Cytogel Pharma, a Darien, CT-based biopharmaceutical development firm, has raised $2.2 million in equity and rights funding, according to an SEC filing. The company, founded in 2002, says that its strategy is to license promising drugs with the intent of eventually selling them to larger companies, according to its website. Centripetal Capital Partners, based in Stamford, CT, lists Cytogel among its portfolio companies.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
